Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)

NCT06576115 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT06576115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06576115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
February 28, 2025
Completion date
July 31, 2027
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma